Alzheimer's Research Laboratory
Alzheimer’s disease is the most common form of dementia. More than 5 million people in the United States are forced to cope with the significant personal, social, and financial distress it causes patients and their families. Treatments that are presently approved by the Food and Drug Administration for the treatment of Alzheimer’s disease can alleviate some of the symptoms but are not curative.
At Barrow Neurological Institute, our team of physicians and scientists is focused on the development of treatments that will delay or slow the progression of the disease. Our research combines laboratory studies of novel compounds with clinical testing of medications under development by our colleagues at pharmaceutical research institutions.
Our main targets are mitochondria, specialized structures that generate most of the energy needed for cellular processes. We have shown that mitochondrial activity decreases as the brain ages and that this decrease is more pronounced in Alzheimer’s disease and in other disorders associated with brain aging, notably Parkinson’s disease. We are therefore investigating various therapeutic approaches that enhance mitochondrial activity and that can be translated into effective treatments for Alzheimer’s and Parkinson’s diseases. Visit the Alzheimer's Research Laboratory Home Page.
The North American Research Committee on Multiple Sclerosis (NARCOMS) is a project of the Consortium of Multiple Sclerosis Centers (CMSC), a nonprofit professional organization for multiple sclerosis (MS) healthcare providers and researchers. NARCOMS management has been affiliated with the Barrow Neuroimmunology Program since 1992. The administrative office of NARCOMS at the University of Alabama - Birmingham (UAB) maintains the largest voluntary patient-driven Multiple Sclerosis (MS) registry in the world. Over the last 15 years, over 35,000 people with MS have participated in the registry by submitting data online or by traditional mail. Visit the NARCOMS Project Home Page.
Fu-Dong Shi Laboratory
The Barrow Neuroimmunology Laboratory is a collaborative effort that encompasses the Neuroimmunology Regular Clinical Service Team, the Clinical Research Team, and the North American Research Committee on Multiple Sclerosis (NARCOMS) Project.
The overall goals of the laboratory program are to improve understanding of innate immunity, inflammatory neurological disease and to develop treatment strategies. The Maalouf Laboratory, headed by Principal Investigator Marwan Maalouf, MD, PhD, is primarily focused on exploring the relationship between mitochondrial function in neuronal cells and neurodegenerative diseases like Alzheimer's and ALS. Recently, Dr. Maalouf and his team have proven that mitochondrial activity deceases as the brain ages. Visit the Fu-Dong Shi Laboratory Home Page.